GovChime
Notice ID: a66fa049719245f4ad70e762c9f99b36Award NoticeAwardedArchived

Chemistry, Manufacturing and Controls and Related Services for Development of Drug Substances

Awarded on August 17, 2026. Full description on SAM.gov.

Awarded tounder 75N95026D00010 (source: SAM.gov award notice)• $49.7M

Overview

Posted
August 17, 2026
Notice type
Award Notice
Set-aside
No Set aside used
NAICS
325411: Medicinal and Botanical Manufacturing
Agency
Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH

Notice details

Office
NATIONAL INSTITUTES OF HEALTH NIAID
Place of performance
Ewing, New Jersey, 08628
Last updated
Oct 28, 2026
First published
Last updated on SAM.gov
Award date
Aug 17, 2026
Award amount (SAM.gov award notice)
$49.7M

Identifiers

Solicitation number
75N95024R00094
Notice ID
a66fa049719245f4ad70e762c9f99b36
Award number (PIID)
75N95026D00010

Description

A competitive multiple award, Indefinite Delivery/Indefinite Quantity (ID/IQ) type contract was awarded, with a ordering period (August 17, 2026 through May 14, 2031). It is anticipated that Task Orders issued against these contracts will most likely be cost-reimbursement, term/completion type Task Orders. Upon analysis of the type of work and all associated costs involved, fixed-price type task orders are usually not feasible due to the absence of precise specifications and difficulties in estimating costs with accuracy. Based upon the uncertainties involved, the Government would assume undue risk in attempting to fit relatively dynamic (science responsive and result-drive) requirement into a fixed-price environment. In these instances, fixed-price task orders would be disadvantageous to the Government, since they do not provide the Government with the flexibility that is needed to reasonably and responsively shift with the evolving needs of this requirement. However, fixed price Task Order may be issued, where appropriate and feasible. 

The Contractor is eligible for Task Orders under Technical Area 1.

The award notice is in relation to Solicitation # 75N95024R00094.

Full description on SAM.gov

Award Overview

Award Number

75N95026D00010

Award Amount (SAM.gov award notice)

$49.7M

Award Date

Aug 17, 2026

Awardee

Awardee UEI

HD6YW88C89J1

Awardee CAGE Code

9MGN5

Awardee Address

Ewing, NJ 08628, UNITED STATES

Original Solicitation

Notice ID: a66fa049719245f4ad70e762c9f99b36

Posted Date: Aug 17, 2026

Original Response Deadline: Not specified

Contacts

Contracting Officer

Primary Contact

Documents

Select documents to download

Showing 10 of 27 items

Document
Source
Agency
Posted Date
File Size
Actions
SolicitationNATIONAL INSTITUTES OF HEALTHAug 17, 2026-
SolicitationNATIONAL INSTITUTES OF HEALTHAug 17, 2026-
SolicitationNATIONAL INSTITUTES OF HEALTHAug 17, 2026-
SolicitationNATIONAL INSTITUTES OF HEALTHAug 17, 2026-
SolicitationNATIONAL INSTITUTES OF HEALTHAug 17, 2026-
SolicitationNATIONAL INSTITUTES OF HEALTHAug 17, 2026-
SolicitationNATIONAL INSTITUTES OF HEALTHAug 17, 2026-
SolicitationNATIONAL INSTITUTES OF HEALTHAug 17, 2026-
SolicitationNATIONAL INSTITUTES OF HEALTHAug 17, 2026-
SolicitationNATIONAL INSTITUTES OF HEALTHAug 17, 2026-

Showing 1 to 10 of 27 results

Lifecycle

  1. 3
    Version 3Award NoticeArchivedCurrent

    Chemistry, Manufacturing and Controls and Related Services for Development of Drug Substances

    Notice a66fa049719245f4ad70e762c9f99b36 on SAM.gov

Other notices for this solicitation

  1. AwardedRelated noticeAug 5, 2026

    Chemistry, Manufacturing and Controls and Related Services for Development of Drug Substances

    Notice f12910af94854c22973bc5b9a6715069 on SAM.gov

  2. AwardedRelated noticeAug 5, 2026

    Chemistry, Manufacturing and Controls and Related Services for Development of Drug Substances

    Notice 015af0d4520f49299f9a6c0b1dfa1ce7 on SAM.gov

  3. AwardedRelated noticeAug 5, 2026

    Chemistry, Manufacturing and Controls and Related Services for Development of Drug Substances

    Notice 16231681029040da913c3d46b0a1785c on SAM.gov

  4. AwardedRelated noticeAug 5, 2026

    Chemistry, Manufacturing and Controls and Related Services for Development of Drug Substances

    Notice 7333428d4e65494e8412615665a3709f on SAM.gov

  5. AwardedRelated noticeAug 5, 2026

    Chemistry, Manufacturing and Controls and Related Services for Development of Drug Substances

    Notice 878697159c5449199f9ccdc865bc376f on SAM.gov

Similar Opportunities

Title
Match
Phase
Deadline
(i)This is a combined synopsis/solicitation for commercial items prepared in accordancewith the format in FAR Subpart 12.6, as supplemented with additional information includedin this notice. This announcement constitutes the only solicitation; proposals are beingrequested, and a separate written solicitation will not be issued. (ii)The solicitation number is 75N98027Q00017. This solicitation is issued as a Notice ofIntent (NOI) for a non-competitive combined synopsis/solicitation to award a contract orpurchase order without providing for full and open competition (including brand-name, ifapplicable). This acquisition is conducted under the authority of FAR 12.603, Streamlined Solicitation for Commercial Products or Commercial Services, and is not expected to exceed the simplified acquisition threshold. Additional authority includes 41 U.S.C. 1901 and FAR 6.302-3(a)(2)(ii). The National Institutes of Health (NIH), Office of the Director, Office of Acquisitions, intends to negotiate and award a purchase order on a non-competitive basis to Purdue University, Purdue Institute for Drug Discovery (DRUG), 575 Stadium Mall Drive, West Lafayette, IN 47907, for the synthesis, scale-up, and characterization of lead Spleen Tyrosine Kinase (SYK) inhibitors in support of the NIH Bench-to-Bedside study "Developing Red Cell-Specific Spleen Tyrosine Kinase (SYK) Inhibitors for Treating Sickle Cell Disease." Rationale for non-competitive award: The proposed acquisition is a continuation of project-specific medicinal chemistry work under the NIH Bench-to-Bedside study "Developing Red Cell-Specific Spleen Tyrosine Kinase (SYK) Inhibitors for Treating Sickle Cell Disease." Dr. Philip S. Low's laboratory at Purdue University is the identified extramural medicinal chemistry collaborator for this project and has performed the prior design and synthesis work associated with the SYK inhibitor candidates being advanced under the study. The Year 1 requirement is specifically for the synthesis, scale-up, and characterization of lead SYK inhibitors S1115 and S1213 for subsequent biological evaluation by NIH investigators. Purdue possesses the project-specific knowledge and experience associated with these compounds. Use of another source would require duplication of prior research before the source could continue the current effort, resulting in delay and technical risk. Based on these circumstances, Purdue University is the only source reasonably available to perform this specific Year 1 requirement. (iii) The solicitation document and incorporated provisions and clauses are those in effect through Federal Acquisition Circular 2026-01, effective 03/13/2026. (iv) The associated NAICS code is 325411, Medicinal and Botanical Manufacturing, and the small business size standard is 1,250 employees. This requirement is not set aside for small business.
-Combined Synopsis11/04/2026
NOTICE OF INTENT – SOLE-SOURCE ACQUISITION Notice No.: The National Institutes of Health (NIH), National Institute of Environmental Health Sciences (NIEHS), intends to award a Firm-Fixed-Price Purchase Order to Creative Biolab Inc. for culture all cells and differentiate them, expand their cell populations to more than 20 million, collect them, verify cell count, and send them back to us. Description of the Requirement The primary objective of this study is to sequence and analyze the 4q35 locus on Chromosome 4 for several years. This locus is a gene-poor and extremely long (>100K) region of DNA that consists of many repetitive sequences which makes sequencing and analysis extremely difficult. To sequence this locus using Nanopore Sequencing technology. To expand the number of samples for our experiment, we looked for a company that can handle numerous cell lines and follow the protocol that we provide. Creative Biolabs is the only company/research institute that has been able to perform differentiation within 3 months and has the ability to follow our protocol with numerous cell lines. Justification for the Proposed Sole-Source Acquisition The Government intends to solicit from a single source pursuant to FAR 6.302-1, Only One Responsible Source and No Other Supplies or Services Will Satisfy Agency Requirements. Only Creative Biolabs was willing to follow our exact protocol and had the logistical capacity to handle the large number of cell lines that we need to analyze, which is vital to research at the National Institute of Environmental Health Sciences. Response Information This notice is not a request for competitive quotations or proposals. However, interested parties that believe they can meet the Government's requirements may submit a capability statement demonstrating their ability to provide the required preventive maintenance and remedial repair services for the specified instrument and meet all applicable technical and operational requirements. The Government will review timely submissions to determine whether another responsible source is capable of satisfying the requirement and whether a competitive acquisition is appropriate. The Government anticipates making an award approximately five (5) calendar days after the closing date of this notice, unless the Government determines that another responsible source can satisfy the requirement. Capability statements must be submitted electronically to verne.griffin@nih.gov no later than 9:00 a.m. EDT on November 13, 2026. Please reference Notice No. 75N98027Q00053 in the subject line of the submission.
-Pre-Solicitation11/12/2026
SAM.gov SOURCES SOUGHT NOTICE Solicitation Number: 75N98027Q00029 Title: Tau radiotracers for Baltimore Longitudinal Study of Aging Classification Code: 6505 NAICS Code: 325414 Description: Biological Product (except Diagnostic) Manufacturing This is a Small Business Sources Sought Notice. This is NOT a solicitation for proposals, proposal abstracts, or quotations. The purpose of this notice is to obtain information regarding: (1) the availability and capability of qualified small business sources; (2) whether they are small businesses; HUBZone small businesses; service-disabled, veteran-owned small businesses; 8(a) small businesses; veteran-owned small businesses; woman-owned small businesses; or small disadvantaged businesses; (3) their size classification relative to the North American Industry Classification System (NAICS) code for the proposed acquisition. Your responses to the information requested will assist the Government in determining the appropriate acquisition method, including whether a set-aside is possible. An organization that is not considered a small business under the applicable NAICS code should not submit a response to this notice. This notice is issued to help determine the availability of qualified companies technically capable of meeting the Government requirement and to determine the method of acquisition. It is not to be construed as a commitment by the Government to issue a solicitation or ultimately award a contract. Responses will not be considered as proposals or quotes. No award will be made as a result of this notice. The Government will NOT be responsible for any costs incurred by the respondents to this notice. This notice is strictly for research and information purposes only. Background: The BLSA was initiated in 1958 and is a multi-disciplinary study of physiologic and psychologic aspects of normal aging in community-dwelling men and women. Since 1994, we have been conducting a longitudinal brain imaging study of selected older adults in the BLSA to characterize individual differences in longitudinal brain changes, to investigate the extent to which these brain changes underlie individual differences in cognitive aging, to identify brain changes that may be predictors of cognitive decline and Alzheimer’s disease (AD), and to assess the impact of potential modulators of brain and cognitive aging. More recently, we have been collecting in vivo measures of brain amyloid and tau, the hallmark pathologies of AD, using PET scanning. The purpose of this acquisition is to acquire FDA- approved second generation tau PET imaging radioligand to perform in vivo Positron Emission Tomography (PET) scans to measure brain tau neuropathology in BLSA participants on a combined PET/computed tomography (CT) scanner. Purpose and Objectives: The purpose of this acquisition is to procure Tau radiotracers for the Baltimore Longitudinal Study of Aging. Project requirements: Independently, and not as an agent of the Government, the Contractor shall provide the following Lantheus products: 70 Tau radioligand doses for the base period. Catalog Number [18F]MK-6240. 70 Tau radioligand doses for option period 1. Catalog Number [18F]MK-6240. 70 Tau radioligand doses for option period 2. Catalog Number [18F]MK-6240. Anticipated period of performance: Base Year: November 18, 2026 – November 17, 2027 Option Year 1: November 18, 2027 – November 17, 2028 Option Year 2: November 18, 2028 – November 17, 2029 Requested Response: The intent of this sources sought notice is to define the procurement strategy (e.g. set-aside, sole source, unrestricted) for a solicitation that is intended to be posted soon. Interested contractors are requested to respond by (1) identifying how their proposed product meets or exceeds the project requirements listed above; and (2) providing product literature, white papers, or capability statements that demonstrate their bona fide ability to supply such an item within the time frame described above. In addition, please state your business size status and whether you are the manufacturer or authorized distributor of the item you propose. Please note that NIH is particularly interested in small business sources. If you are a small business, please state the type of small business (small business; HUBZone; service-disabled, veteran-owned; 8(a); veteran-owned; woman-owned; or small disadvantaged businesses) and your size classification relative to the North American Industry Classification System (NAICS) code for the proposed acquisition. Your responses to the information requested will assist the Government in determining the appropriate acquisition method, including whether a set-aside is possible. The respondent must also provide their DUNS number, organization name, address, point of contact, and size and type of business (e.g., 8(a), HubZone, etc.), pursuant to the applicable NAICS code and any other information that may be helpful in developing or finalizing the acquisition requirements. The information submitted must be must be in an outline format that addresses each of the elements of the project requirements and in the capability statement /information sought paragraphs stated herein. A cover page and an executive summary may be included but is not required. The response must include the respondents’ technical and administrative points of contact, including names, titles, addresses, telephone and fax numbers, and e-mail addresses. All responses to this notice must be submitted electronically to the Contracting Officer. Facsimile responses are NOT accepted. The response must be submitted to Kevin Alvarez, Contracting Officer, at e-mail address kevin.alvarez@nih.gov. The response must be received on or before October 27, 2026, 9:00am, Eastern Time. Disclaimer and Important Notes: This notice does not obligate the Government to award a contract or otherwise pay for the information provided in response. The Government reserves the right to use information provided by respondents for any purpose deemed necessary and legally appropriate. Any organization responding to this notice should ensure that its response is complete and sufficiently detailed to allow the Government to determine the organization’s qualifications to perform the work. Respondents are advised that the Government is under no obligation to acknowledge receipt of the information received or provide feedback to respondents with respect to any information submitted. After a review of the responses received, a presolicitation synopsis and solicitation may be published at SAM.gov. However, responses to this notice will not be considered adequate responses to a solicitation. Confidentiality: No proprietary, classified, confidential, or sensitive information should be included in your response. The Government reserves the right to use any non-proprietary technical information in any resultant solicitation(s).
-Market Research10/27/2026
Signed Award attached.
-AwardedOpen
Firm Fixed Price, Sole Source. Cartridge Actuated Devices is the only source approved contractor for this item.
-AwardedOpen

Additional Details

Solicitation Number

75N95024R00094

Archive Date

Sep 1, 2026

Office Address

BETHESDA, MD, 20892